Advocacy intelligence hub — real-time data for patient organizations
COAGADEX: FDA approved
COAGADEX is indicated in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with mild and moderate hereditary Factor X deficiency.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
COAGADEX
Bio Products Laboratory Limited
COAGADEX
(Coagulation factor X (human))Orphan drugBio Products Laboratory Limited
12.1 Mechanism of Action COAGADEX temporarily replaces the missing Factor X needed for effective hemostasis. Factor X is an inactive zymogen, which ca...